Navigation Links
3-V Biosciences Promotes Stephen R. Brady to Chief Business Officer
Date:2/10/2011

MENLO PARK, Calif., Feb. 10, 2011 /PRNewswire/ -- 3-V Biosciences, Inc. announced today Stephen R. Brady has been named as Chief Business Officer.  

(Logo:  http://photos.prnewswire.com/prnh/20100513/LA04336LOGO)

"Steve's contributions have been pivotal as a member of the team during his tenure at 3-V," said Merdad V. Parsey, MD, PhD, 3-V's Chief Executive Officer.  "I look forward to working with him as we continue to build the 3-V team and advance the company's programs."

Mr. Brady joined the 3-V team in 2010 as Vice President, Corporate Development, Strategy & Operations, with management responsibility for the company's business functions, including strategy, finance and legal.  Prior to joining the company, Mr. Brady was the Vice President of Corporate Development of Proteolix, Inc. where he had primary responsibility for Proteolix's business development activities, resulting in the sale of the company to Onyx Pharmaceuticals, Inc.  Previously, Mr. Brady served as Senior Corporate Counsel at Lexicon Pharmaceuticals, Inc., where he served in business development, communications and corporate legal capacities. Prior to his tenure with Lexicon Pharmaceuticals, Inc., Mr. Brady was a Vice President with Lazard Venture Advisors, a division of Lazard Freres & Co., LLC, and an associate in the New York and San Francisco offices of Morrison & Foerster LLP.  Mr. Brady received a B.A. in English from the University of Oregon and a LL.M. from the New York University School of Law.

About 3-V Biosciences3-V Biosciences, Inc. is a privately-held biopharmaceutical company dedicated to discovering, developing and ultimately commercializing novel therapeutics that target host cell factors required for infection, thereby avoiding many of the shortcomings of traditional pathogen-directed approaches.  The company is located in Menlo Park, California and is financed by The Column Group, Kleiner Perkins Caufield Byers, and New Enterprise Associates.

For additional information on 3-V Biosciences, please visit www.3vbio.com.Contact informationMerdad V. Parsey, MD, PhDChief Executive Officer650-561-8600
'/>"/>

SOURCE 3-V Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Announces Presentation at the 13th Annual BIO CEO & Investor Conference
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2010 Financial Results
3. DARA BioSciences to Present Live at RetailInvestorConferences.com on February 3
4. Avantra Biosciences Launches Multiplex System for Faster, Easier Quantification of Cancer Protein Biomarkers
5. Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration
6. Cell Biosciences Launches New Platform for Multiplex Western Blot Detection
7. Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences
8. Ambit Biosciences Initiates Two Phase I Clinical Trials
9. Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
10. Cell Biosciences Announces US Patent Issuance
11. Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and ... today announced the signing of a three-year exclusive ... will deploy a dedicated sales team to introduce ... U.S., primarily focused in 13 states in the ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... 2017 , ... Crossover Symmetry , an evidence based ... lifestyle company that provides Human Performance Training and education to tactical athletes. Together ... military officers and others in service through the development and conditioning of overall ...
(Date:4/21/2017)... ... April 21, 2017 , ... Northern California Medical ... Care Spring Symposium on April 1, 2017 in Santa Rosa. This well-attended annual ... healthcare providers an opportunity to learn about cutting edge treatments, to collaborate, share ...
(Date:4/21/2017)... ... April 21, 2017 , ... BrightStar Care Salt Lake City, a ... Care of Utah (APCUT) and has appointed Rex Wheeler as its new Director of ... for our agency and our ability to provide quality care to the community,” said ...
(Date:4/21/2017)... ... , ... During April 21-23, Super-Sod will join the vendor market of the ... everyone — from the avid gardener to the landscape admirer — during the three-day ... in a grand venue, and we are certainly looking forward to participating in this ...
(Date:4/21/2017)... ... April 21, 2017 , ... National pest management association survey conducted ... of bed bug infestations over the 5-year period. In 2015 10% or US$750 million ... of bed bug infested properties. , The health and economic consequences of bed ...
Breaking Medicine News(10 mins):